Rockville company’s drug to be tested in U.S.

Synthetic Biologics Inc., of Rockville, which develops and commercializes medicines derived from synthetic biology, said its Swedish sublicensee, Meda AB, received approval from U.S. regulators to conduct a Phase II study of a new drug being developed for the treatment of fibromyalgia.

The Phase II proof-of-concept study will be conducted at 25 clinics in the U.S.

The drug, flupertine, is currently approved and marketed by Meda for the treatment of pain in countries outside of the U.S. Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms.

Leave a Reply

Your email address will not be published. Required fields are marked *